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ABSTRACT 
Detection of Oxidation in Human Serum Lipoproteins.   
(May 2004) 
Christine Lee Myers, B.A., The Colorado College 
Chair of Advisory Committee:  Dr. Ronald D. Macfarlane 
A method for the oxidation of lipoproteins in vitro was developed using the free 
radical initiator, 2,2’-azobis-(2-amidinopropane) dihydrochloride (AAPH).  Following in 
vitro oxidation, the susceptibility to oxidation of the serum samples was studied using 
density gradient ultracentifugation and matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF-MS).   
 Shifts in mean buoyant density of the lipoprotein particles, specifically low 
density lipoprotein (LDL) and high density lipoprotein (HDL), were observed in the 
density profile following centrifugation.  The degree of shift in the density proved to be 
proportional to the extent of oxidation.  Changes in apolipoproteins were studied with 
MALDI-TOF-MS.  Observed variations in the mass spectra include m/z shifts due to 
chemical modifications and change in isoform distributions. 
 The oxidation procedure and analysis techniques were applied to a clinical 
application to study the effects of table grape consumption on lipoprotein susceptibility 
to oxidation.  The main objective of the research, to show feasibility that these methods 
could be used in a clinical setting, was achieved. 
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INTRODUCTION 
 
 Complications from cardiovascular disease (CD) are the most common causes of 
death in western society.  In their most recent report, The American Heart Association 
listed cardiovascular disease as the number one killer of Americans in the year 2001 (1).  
It has been well established that hypercholesterolemia is an important cause of CD.  No 
matter how successfully hypercholesterolemia is dealt with, however, CD will not 
disappear because high cholesterol levels are by no means the only causative factors. It 
has become socially necessary to elucidate the mechanism of atherogenesis and find 
ways of dealing with the resulting diseases (2).  The list of factors inducing CD is too 
long to thoroughly cover here.   
 Oxidation of lipoproteins, specifically low density lipoprotein (LDL), was 
discovered in the early 1980s (3).  Since then, the number of papers published on 
oxidized LDL (oxLDL) alone has increased exponentially.  Results indicate that 
production and accumulation of oxLDL increase in patients with vascular disease, and 
that oxLDL levels could provide useful diagnostic information. 
 
Lipoproteins 
 Lipoproteins are complex particles in circulation that are responsible for lipid 
 
_____________ 
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 transport.  Each lipoprotein particle contains a hydrophobic core of cholesterol esters 
and triglycerides, surrounded by a hydrophilic surface of unesterified cholesterol, 
phospholipids, and proteins.  Also incorporated into the particle are lipid soluble 
antioxidant molecules such as α-tocopherol (vitamin E) and β-carotene.   
 Three major classes of lipoproteins exist in a human serum sample; very low 
density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein 
(HDL).  There also exist other classes such as chylomicrons and intermediate density 
lipoprotein (IDL), as well as subclasses.  These lipoprotein classes differ in their 
metabolic pathways, size, lipid and protein composition, and density.  Table 1 
summarizes the compositional differences between lipoprotein classes.  Each 
lipoprotein, regardless of class, has a similar spherical structure. 
 
Table 1. Composition of human serum lipoproteins (4). 
Weight % of Total Lipoproteins 
 
Component 
 
Chylomicrons VLDL IDL LDL HDL 
Phospholipid 
 
6-9 16-20 20-24 24-30 24-30 
Free Cholesterol 
 
1-3 4-8 8-9 9-12 2-5 
Cholesteryl Esters 
 
3-6 9-13 13-28 28-30 10-20 
Triglycerides 
 
82-86 50-60 12-50 7-11 4-5 
Proteins 
 
1-2 8-11 11-20 20-22 41-58 
 
Density (kg/L) 
 
 
0.93-1.006 0.95-
1.006 
1.006-
1.019 
1.019-
1.063 
1.063-
1.21 
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 While all lipoproteins are susceptible to lipid peroxidation, LDL is the most 
sensitive due to its composition of lipids, proteins, and antioxidant particles (5).  LDL is 
the main cholesterol carrier in plasma.  Its purpose is the transportation of cholesterol to 
peripheral tissues in the body.  LDL is comprised of cholesterol esters and 
phospholipids, with very few triglycerides or unesterified cholesterol molecules.  Each 
LDL particle contains one molecule of apolipoprotein B-100 (apo B) that acts as the 
receptor for LDL binding.  The molecule of apo B covers much of the lipoprotein 
surface as shown in Figure 1, not just a small portion as often depicted in schematic 
sketches.  The apo B alone accounts for approximately 20% of the total LDL volume (6), 
and acts as the ligand for the receptor that allows cholesterol influx (3).  Also present are 
small amounts of apolipoproteins C-III and E.  LDL particles exist with a variety of 
chemical compositions, sizes, and densities.   
Evidence indicates that certain characteristics make LDL particles more or less 
susceptible to oxidation in vitro.  Fatty acid composition of the lipoprotein particle is 
important.  As polyunsaturated fatty acids (PUFAs), such as linoleic acid (18:2), are the 
primary source of the radical chain reaction initiation, a high proportion of PUFAs 
indicate greater risk of oxidation.  Conversely, a high proportion of monounsaturated 
fatty acids, such as oleic acid (18:1) tends to protect against oxidation (7).  Small dense 
LDL particles, which have been in circulation a longer time period than large buoyant 
particles, are more sensitive to in vitro oxidation than larger particles (8,9,10).  These 
small particles show lower concentrations of lipid soluble antioxidants, and it has been 
shown in vivo that longer plasma residence time increases the net oxidative insult on  
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phospholipids 
unesterified cholesterol 
apo B 
 
Figure 1. Structure of a low density lipoprotein (Adapted from 11). 
 
the particle, yielding them more susceptible to oxidation (10).  Increased lipoprotein 
glycation has also been shown to increase oxidation susceptibility due to modifications 
of the lipoprotein and inactivation of potential antioxidants (12).  Native lipoprotein 
concentration, however, is not a crucial factor in the susceptibility to in vivo oxidation 
(2).   
 Elevated levels of LDL in serum is a predictor for CD due to LDLs ability to 
accumulate in the cells of the arterial intima; however native LDL is unable to initiate 
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foam cell formation which leads to arterial plaque.  Postsecretory modifications of LDL 
must somehow affect its atherogenic potential.   
 Native LDL is taken out of the bloodstream via a receptor that recognizes a 
specific group of positively charged lysine residues on the apo B molecule (13).  This 
receptor is highly regulated by cholesterol content in the peripheral tissues.  An early 
step in atherosclerosis is the formation of a fatty streak consisting of foam cells, which 
are macrophages or endothelial cells laden with cholesterol.  Due to its regulation, the 
classical LDL receptor is unable to provide a pathway for the necessary amount of 
cholesterol to enter the macrophages or endothelial cells for foam cell formation. This 
indicates there exists another receptor for LDL, known as a scavenger receptor.  Patients 
who completely lack classical LDL receptors are still able to form foam cells, also 
indicating a scavenger pathway (3). 
 Experimentation showed that acetylation of LDL produced a modified particle 
that was recognized by the scavenger receptor on macrophages (14,15).  No 
physiological evidence could support the acetylation of LDL in vivo, however.  Similar 
uptake was achieved with malondialdeyhde-conjugated LDL (16), but again 
physiological evidence was lacking.  Lipoproteins incubated with endothelial cells (17) 
and oxidized lipoproteins (17) are also taken up the scavenger receptor.  All of these 
modifications increase the net negative charge of the LDL by derivatizing amino groups 
on the apo B molecule.  For example, lysine residues, which are positively charged at 
physiological pH, are neutralized, thus increasing the net negative charge of the particle.  
Unlike some of the other modifications, oxidation could be explained by multiple 
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physiological mechanisms, and oxLDL has been accepted as the natural ligand for the 
scavenger receptor.  The rate of uptake of modified particles by the scavenger receptor is 
much higher than uptake of native LDL by the classical receptor, and the scavenger 
receptor does not recognize native LDL (15,17). 
 
In Vivo Oxidation 
 Oxidation of LDL affects much more than the affinity for the scavenger receptor 
as opposed to the classical LDL receptor.  Most importantly, the lipid portion of oxLDL 
is cytotoxic to most cells (18,19).  Oxidized particles also affect macrophage lipid 
loading (20), platelet aggregation, monocyte migration, can inhibit endothelial cell-
dependent arterial relaxation (7), and activate the immune system (21). 
 The mechanism for in vivo oxidation of lipoproteins is believed to be a free 
radical driven lipid peroxidation chain reaction, shown in Figure 2.  Oxidation is 
initiated by a free radical attack on a double bond associated with a polyunsaturated fatty 
acid (PUFA) in the lipoprotein.   Hydrogen abstraction from the methylene (CH2) group 
forms a lipid radical that quickly undergoes molecular rearrangement to a more stable 
form, known as a conjugated diene.  The conjugated diene then reacts with molecular 
oxygen creating a PUFA peroxyl radical.  This radical may attack an adjacent PUFA and 
abstract a hydrogen to form a hydroperoxide radical and yet another lipid radical.  This 
reaction results in chain propagation. Peroxidation of other lipids also occurs, such as 
oxidation of cholesterol to yield oxysterols (22), and phosphatidyl choline to form 
lysophosphatidyl choline (23). 
 7 
 
CH3 
+ H · 
- H · 
O 
OH 
O 
O · 
· 
· 
H3C CH3 
H3C CH3 
H3C CH3 
H3C 
CH3 
H3C fatty acid (PUFA) 
unstable carbon radical 
conjugated diene 
peroxyl radical 
lipid hydroperoxide 
 
 
Figure 2.  The chain reaction of lipid peroxidation (Adapted from 7). 
 
Lipid hydroperoxides eventually break down into shorter chain aldehydes.  These 
short chain aldehydes are responsible for binding to the protein constituents in the 
lipoprotein particles.  The aldehydes bind to amino acid side chains, increasing the net 
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negative charge of apo B in reactions such as imination (Schiff base formation). This 
change in charge state makes it impossible for the oxidized LDL to bind to the classical 
LDL receptor.  Apo B is also fragmented after exposure to lipid peroxidation 
byproducts. 
Present in native LDL are certain antioxidants.  The most predominant is the 
lipid soluble antioxidant α-tocopherol (vitamin E).  Alpha-tocopherol scavenges peroxyl 
radicals and breaks the peroxidation chain reaction (24).  Beta-carotene, a carotenoid and 
the precurser to vitamin A, is another antioxidant present in the lipoprotein.   Beta-
carotene quenches singlet oxygen (25).  These antioxidants form radicals with such low 
reactivity that termination almost always occurs.  Other antioxidants that are important 
to lipoprotein oxidation are ubiquinol (26) and HDL (27,28).  HDL can itself be 
oxidized, however it also acts as a strong antioxidant for LDL particles.  HDL contains 
several enzymes, such as paraoxonase (PON), that are able to cleave oxidized lipids, and 
therefore inhibit LDL oxidation.  Apolipoprotein A-I, the major HDL lipoprotein, can 
remove oxidized lipids from cells, as well as influence the cell’s ability to oxidize LDL 
particles (29). 
Oxidation of lipoproteins does not occur in the anti-oxidative atmosphere of the 
bloodstream (30), and in fact very little fully oxidized lipoprotein circulates in the 
bloodstream (31).  Rather, as shown in Figure 3, oxidation takes place in the extracellular 
space of the arterial intima (32).  Native LDL particles are able to transfer in and out of the 
arterial wall (33).  Once inside the intima, lipoproteins have less antioxidant protection and 
are exposed to pro-oxidants such as endothelial cells.  Minimally modified LDL 
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(mmLDL) is formed, which is a slightly oxidized LDL particle.  In mmLDL PUFA 
oxidation on phospholipids has occurred, but the particle is still recognizable to the 
classical LDL receptor (34,35). The mmLDL particles stimulate endothelial cells to 
release monocyte chemotactic protein-1 (MCP-1) and macrophage colony stimulating 
factor (M-CSF) (36).  MCP-1 aids in the migration of monocytes through the endothelial 
membrane from the lumen to the arterial intima.  Once in the subendothelial space, M-CSF 
induces monocyte differentiation to form macrophages.  Minimally modified LDL is 
oxidized further until all antioxidants are depleted and the apo B is derivitized.  This fully 
oxidized LDL particle (oxLDL) is no longer recognizable to the classical LDL receptor, 
but is recognized by scavenger receptors on macrophages.  Uptake of oxLDL by the 
scavenger receptor is not regulated by intracellular cholesterol levels.  Appreciable 
accumulation of neutral lipids therefore occurs, and the macrophage becomes laden with 
massive amounts of lipids.  So much lipid is present that it forms lipid droplets, which 
characterize foam cells.  Foam cells are accepted as a hallmark of early atherosclerotic 
lesions (2). 
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Figure 3. The role of oxLDL in atherosclerosis (36). 
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In Vitro Oxidation 
 In order to understand the in vivo mechanisms and consequences of oxidation, 
many studies have been performed in vitro.  There are two approaches to studying 
oxidation in vitro, direct and indirect measurements.  Direct measurements analyze 
oxidized lipoproteins or oxidation byproducts present in a plasma or serum sample.  
There is little oxidized lipoprotein in any plasma or serum sample as they are quickly 
filtered out of the bloodstream (2,31).  Lack of sensitivity of the current methods for 
very low concentrations of oxLDL make direct measurements difficult.  Some of the 
oxidation byproducts that can be analyzed include mmLDL, which exists in the 
bloodstream at higher concentrations than oxLDL, individual antioxidant concentrations, 
volatile hydrocarbons, and levels of auto-antibodies to oxLDL (24). 
Indirect measurements take into account the susceptibility of a sample to 
oxidation.  By exposing a sample to oxidative stress and mimicking in vivo oxidation, 
the oxidative response and therefore susceptibility to oxidation of the sample can be 
monitored.  There are two main phases in LDL oxidation (Figure 4). The first phase, the 
lag phase, occurs when the lipoprotein is exposed to oxidative stress, but endogenous 
antioxidants protect the lipids from peroxidation. There is some oxidation of the lipids in 
the lipoprotein, but at a slow rate due to the protective abilities of the antioxidants.  Once 
all the antioxidants are depleted, oxidation enters the propagation, or second, phase.  The 
rate of oxidation increases dramatically as there is nothing left to protect the lipoprotein 
particle.  By measuring the length of the lag phase, it is possible to determine the 
susceptibility of the sample and surrounding medium to oxidation. 
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Propagation Phase Lag Phase 
Time 
 
 
Figure 4. Typical graph of LDL oxidation. 
 
Many physiochemical changes occur in the lipoprotein during oxidation.  These 
multiple attributes make many types of analysis possible on intact oxidized lipoproteins, as 
well as byproducts from the oxidation process.  Some of these attributes are listed in Table 
2.   
Through many in vitro studies, differences in lipid composition between native 
and oxidized LDL have been established.  Following in vitro oxidation of LDL, there 
exist lower concentrations of cholesterol ester, unesterified cholesterol, phospholipids, 
and triglycerides (37,38) and complete consumption of endogenous antioxidants (6).  
Phospholipids are immobilized, showing less movement in the particle (39).  Over 50% 
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of the phosphatidylcholine is converted to lysophosphatidylcholine (17,37,40).  The 
increase of lysophosphatidylcholine can alter molecular ordering on the surface of the 
lipoprotein particle, and oxidation of core lipids can change stability and structure.   
Levels of conjugated dienes increase in the oxidized particle because of its stability.  
Aldehyde concentration in the oxidized sample also increases, as they are a final 
endproduct of lipid peroxidation.   
 
Table 2. Differences in oxLDL compared to native LDL. 
• Increased density 
• Increased conjugated diene content 
• Increased aldehyde content 
• Increased electrophoretic mobility 
• Decreased recognition by the classical LDL receptor 
• Increased protein fragments from apo B 
• Increased native fluorescence at 430 nm with excitation at 360 nm 
• Decreased endogenous antioxidants 
 
 
This change in lipid content is enough to affect many physiochemical properties.  
The buoyant density of the lipoprotein is increased significantly due to the change in 
lipid content, with oxLDL having densities up to 1.08 kg/L (17,40). Furthermore, 
examination of changes in particle density profiles can prove that the entire population 
of particles, not just a subpopulation, is being oxidized (41).  Conjugated diene content, 
an intermediate in the radial chain reaction, can be easily monitored 
spectrophotometrically at 234 nm.  Aldehyde content, too, can be used as an analysis 
tool.  Malondialdehyde (MDA), one of the short aldehydes formed, is the peroxidation 
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byproduct measured in the thiobarbituric acid reactive substances (TBARS) assay.  
MDA is not lipid soluble, and is released from the oxidized particle into the surrounding 
aqueous phase (5).  It is also one of the most abundant aldehydes in an oxidized sample. 
Another highly studied aldehyde is 4-hydroxynonenal (42).   
Protein changes due to oxidation have also been elucidated using in vitro 
oxidation.  It is well known that many byproducts of lipid peroxidation, especially 
aldehydes, have enough chemical reactivity to derivatize the apo B molecule (6,43).  
Apo B can also be directly modified by oxidative damage (44).  In a fully oxidized LDL 
particle, the apo B is fragmented into shorter peptide chains, and these chains are bound 
to fragments of oxidized fatty acid.  Most protein fragments  (80-90%) remain associated 
with the lipoprotein particle (37).  
Like lipid content, there are significant changes in amino acid content of the LDL 
particle before and after in vitro oxidation. Following oxidation, there is a decrease in 
reactive amino groups on the apo B molecule (37).  There are significant modifications 
in proline, methionine, histidine, and lysine (45), which is consistent with other studies 
regarding the susceptibility of amino acids to oxidation (46).  A significant increase in 
aspartic acid was also seen (45), which is compatible with previously seen oxidative 
opening of the histidine-imidazole ring to convert it to aspartic acid (47). 
In vitro oxidation induces reactions between lipid and protein moieties.  Free 
aldehydes react with free amino groups on lysine residues, and neutralize a cluster of 
positive charges (37,48).  The increased negative charge on the particle results in 
decreased recognition by the classical LDL receptor (37,48) and increased recognition 
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by the scavenger receptor (49).  Modification of as little as 5% of the lysine residues can 
result in decreased recognition by the classical LDL receptor (37).  The change of charge 
state also results in higher electrophoretic mobility (17,50).  
Some of the lipid-protein adducts that form during oxidation are N-substituted 
amines, or Schiff bases.  These compounds contain an imine in conjunction with an 
electron-donating goup, often a double bond.  They result in native fluorescence of the 
oxidized particle at 430 nm, with an excitation of 360 nm, which is characteristic of 
Schiff base fluorescence (5,48,51,52).   
There are many ways to simulate in vivo oxidation.  One method is by addition of 
azo compounds, or diazenes, which act as free radical initiators (Figure 5) (27,53,54). 
 
 
R-N=N-R  → N2 + 2R• (Reaction 1) 
R• + R• →  R-R  (Reaction 2) 
R• + O2 → RO2•  (Reaction 3) 
 
Figure 5. Thermal decomposition of azo compounds. 
 
Thermal decomposition of the compounds yield molecular nitrogen and two 
carbon radicals (Reaction 1).  Because the carbon radicals are formed in close proximity, 
many recombine to form nonradical products (Reaction 2).  Others will react with 
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molecular oxygen to form peroxyl radicals (Reaction 3).  A specific azo compound used 
frequently in the oxidation of lipoproteins is 2,2’-azobis-(2-amidinopropane) 
dihydrochloride (AAPH) (Figure 6) (55,56,57).   
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Figure 6.  Structure of AAPH. 
 
 AAPH is hydrophilic, and initiates radical production in the aqueous phase.  
Kinetic studies have shown that the rate of decomposition is dependent on temperature, 
solvent, and pH.  The concentration of AAPH is also important, and has been shown to 
be directly proportional to the radical production.  In water at a pH of 7 and a 
temperature of 37° C, the half-life of AAPH is 175 hours.  The rate of radical production 
can therefore be considered constant for the first few hours of any experiment (55). 
 AAPH has been shown to react with micelle-like particles, phospholipid 
liposomes, and erythrocyte membranes.  It is capable of oxidizing both lipid and protein 
moieties (55).   Structurally, lipoproteins are very similar to these particles and 
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comparisons of the affectivity of AAPH can be made.  The precise mechanism of how 
AAPH and many other oxidizing agents interact with LDL remains unclear. 
 AAPH is not present naturally in biological systems, but it is a useful tool in 
studying free radical damage and inhibition nonetheless.  It produces peroxyl radicals in 
the aqueous phase at a constant rate, which can be controlled through environmental 
factors.  These radicals initiate the radical chain reaction that leads to complete oxidation 
of a lipoprotein particle.  AAPH is inexpensive, and can be handled easily and safely. 
 
Thiobarbituric Acid Reactive Substances (TBARS) Assay 
 The TBARS assay was first introduced in 1944 (58), and is now one of the oldest 
and most frequently used methods for monitoring peroxidation of biological samples.  
The concentration of MDA, one of the short aldehydes produced by lipid peroxidation, 
in a sample is believed to be proportional to the amount of oxidation.  In the TBARS 
assay, MDA reacts with thiobarbituric acid (TBA) in an acidic environment to produce a 
red pigment.  The pigment can then be analyzed using ultraviolet spectrophotometery at 
534 nm, or fluorescence with an excitation wavelength of 515 nm.   
 Each MDA molecule reacts with two TBA molecules (Figure 7).  The reaction is 
believed to be initiated by a nucleophilic attack, followed by a dehydration.  This forms 
the 1:1 (MDA:TBA) intermediate, which then undergoes similar reactions to form the 
final 1:2 (MDA:TBA) adduct (59).  
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Figure 7. Formation of the TBARS pigment. 
 
 Unfortunately, the TBARS assay is not specific to MDA.  The acidity and 
elevated temperature of the assay render most carbonyl compounds susceptible to 
nucleophilic attack by TBA (60).  While some of the reactions yield yellow or orange 
chromophors that can be differentiated from the desired product, others yield red 
pigments that are indistinguishable from the 1:2 (MDA:TBA) adduct.  Another problem 
with the TBARS assay is the effect of environmental variability.  Many factors such as 
pH, type of acid used, temperature, buffers, and detergents (to list a few) can drastically 
alter the outcome of the assay (60).   
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 There are two ways to calculate the concentration of MDA present in a sample; 
the published extinction coefficient or a calibration curve.  The extinction coefficient of 
the MDA:TBA complex was experimentally determined to be 1.56 X 105 M-1cm-1 at pH 
0.9 (61).  Many studies still use this value while calculating total TBARS concentration, 
regardless of whether or not the same experimental procedure was used (62,63,64).   
 A calibration curve for the concentration of MDA in a sample can be produced 
using 1,1,3,3-tetramethoxypropane or 1,1,3,3-tetraethoxypropane (61).  When placed in 
aqueous acid, the molecule is hydrolyzed yielding its conjugate aldehyde, MDA, and an 
alcohol (Figure 8).   
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Figure 8. Hydrolysis of 1,1,3,3-tetramethoxypropane. 
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 Reliance on a calibration curve is tenuous at best, because reaction conditions 
may be different between the sample and the standard to a degree that color formation is 
affected (60,64). 
 Despite a plethora of problems, the TBARS assay is still widely used.  The 
success of the assay is due, in part, to the ease with which it can be performed.  The 
reagents are inexpensive and easy to purchase, and most laboratories have the 
instrumentation necessary for analysis.  While a TBARS assay is generally not the sole 
component of any experiment today, it is oftentimes used in conjunction with another 
type of analysis such as chromatography (64,65), electrophoresis (50), fluorescence 
detection (12,51), other assays (63, 66,67), or electron spin resonance (39).   
 
Density Separations 
 Lipoproteins have historically been defined by their buoyant densities.  In order 
to separate the lipoprotein classes used as references, ultracentrifugation was used.  The 
methods used, however, were time consuming and tedious.  More current research has 
developed separation methods that do not have many of the drawbacks seen previously. 
 Density gradient ultracentrifugation methods can be described as either rate or 
isopycnic separations.  For rate separations, a heterogeneous environment of a sample 
layered either over or under a different density solution is utilized.  The particles float or 
sediment through the density gradient at different velocities depending mainly on their 
buoyant densities.  In isopycnic separations, the particles to be separated must be in 
equilibrium with the surrounding density gradient.  At this point, the density of the 
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particles can be determined by their position in the gradient.  Many separations are a 
mixture of the two methods.  At first a separation can be based on rate as the particles 
move in the gradient, but as they reach equilibrium with the gradient the process 
becomes isopycnic.   
 Density gradients can be artificially created before the ultracentrifugation step, or 
can be self-generating during the ultracentrifugation.  Self-generating gradients are easy 
to produce and have predictable thermodynamic properties, such as slope, concentration 
range, isoconcentration point, and time necessary to reach equilibrium (68).  However, 
most require long ultracentrifugation times for gradient formation.  To overcome this 
problem, preformed discontinuous gradients are utilized.  Solutions of decreasing 
density are layered on top of each other before the centrifugation step.  During 
ultracentrifugation, the particles migrate to the solution of identical density.  If the 
separation were stopped at this point, it would be a non-equilibrium separation.  If the 
separation is continued, however, the steps become continuous and an equilibrium 
separation can be obtained.  Time required for an equilibrium separation can be 
decreased significantly by carefully choosing the concentration of each density step.  
Preformed discontinuous gradients are labor intensive, can require special equipment, 
and can be a source of inconsistency in the separation. 
 An ideal solute used for a density gradient separation would have a number of 
characteristics.  Recent research has shown that cesium bismuth EDTA (CsBiY) and 
sodium bismuth EDTA (NaBiY) have many of the ideal properties for a density gradient 
forming solute (69). 
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 There are several methods used for collecting and or measuring separated 
lipoproteins, such as fraction collection pumps (70,71,72), a tube cutting method (73), 
and pre-staining the lipoproteins and imaging the lipoproteins in the tube following 
separation (69,74,75,76,77).  Utilizing digital photography improved the pre-
staining/photographic method by making it possible to generate a density profile in 
much less time than other methods require.  Also, photography is the only technique 
whose resolution depends only on the separation and not on the collection method.  Dyes 
commonly used for lipoprotein analysis are either lipophilic or protein stains.  
 
Fluorescence 
 Naturally occurring lipids, like the ones in lipoproteins, do not have 
chromophores that are suitable for many studies.  Fluorescent probes have been utilized 
to study kinetic processes, cellular localization, and quantification of lipid classes.   
There are three main types of fluorescent probes used to study lipoproteins:  lipid 
analogs, lipid-soluble dyes, and protein modifiers (78).  Fluorescent probes can simplify 
experimental design when used properly. 
 Fluorescent phospholipid analogs have proven to be very useful in lipoprotein 
analysis because they incorporate themselves in the particle surface, and act much like a 
native phospholipid.  Fluorescence measurements of suitably stained lipoprotein samples 
can detect low concentrations of lipoproteins without background interference.  A 
widely used probe of this class is 7-nitrobenz-2-oxa-1,3-diazol-4-yl ceramide (NBD), 
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shown in Figure 9.  Extensive studies have proven that NBD resides in the polar region 
of the lipoprotein (79,80).   
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Figure 9. Structure of NBD. 
 
It is thought that the hydrophilic domain in NBD causes it to loop back towards 
the surface of the membrane, where there exists a more polar environment.  This 
phemonena also decreases the time necessary for lipoprotein staining.  NBD has a large 
Stokes shift and broad absorption and emission peaks in the visible range (Figure 10).  It 
is sensitive to the polarity of its environment, exhibiting a blue shift in emission 
wavelength maximum with decreasingly polar solvents (81).  NBD staining can be used 
to quantitate the amount of lipoprotein in a sample (69), and is able to successfully stain 
lipoproteins when added to a serum sample (82).  
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Figure 10. Absorption and emission spectra of NBD aminohexanoic acid in methanol 
(83). 
 
 Another fluorescent probe utilized in lipoprotein analysis is Nile Red (NR), also 
referred to in literature as 9-diethylamino-5H-benzo[α]phenoxazine-5-one, or Nile Blue 
A-oxazone (Figure 11).  NR preferentially stains neutral lipids, such as cholesterol esters 
and triglycerides, and resides in the hydrophobic domain of the lipoprotein.  Upon 
saturation of the lipid core, however, NR will interact with the surface lipids (84).   
Unlike NBD, no literature cites the success of staining lipoproteins with NR by 
adding the probe to a serum sample.  NR exhibits a large Stokes shift, and broad 
absorption and emission peaks (Figure 12).   
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Figure 11.  Structure of Nile Red. 
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Figure 12. Absorption and emission spectra of Nile Red bound to a phospholipid bilayer 
membrane (85). 
 
NR is a solvochromic dye, a probe whose absorption bands change in intensity, 
shape, and position depending on the polarity of the solvent (86). The excitation and 
emission maxima shift over a span of 100 nm when placed in solvents of differing 
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polarity (87).  The shape of both the excitation and emission spectral curves changes as 
well, indicating specific solvent effects such as hydrogen bonding (87).  Preliminary 
studies have shown perceptible changes in fluorescent profiles between native LDL and 
oxLDL, due to the differing lipid compositions of the particle.  The oxLDL spectra are 
broader, and shifted to a longer wavelength (88).  Acetylation of LDL only modifies the 
lysine residues and does not change the lipid composition.  As expected, no change in 
NR fluorescence was observed between native and acetylated LDL (88). 
 
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry  
 In 1988, Karas and Hillenkamp introduced a new ionization method for mass 
spectrometry of bioorganic compounds, especially non-volatile compounds, termed 
Matrix-Assisted Laser Desorption/Ionization (MALDI) (89).  This soft ionization 
technique involves the use of a matrix, which consists of a solid that has a high 
absorbance in the ultraviolet region (90).  A matrix has two major functions, absorption 
of the energy from an ultraviolet (UV) laser, and isolation of the sample molecules from 
each other (91).  Following absorption of laser energy by the matrix, energy transfer to 
the sample molecules occurs in an efficient and controllable process.  Analyte molecules 
are spared from excessive energy that would result in their decomposition.  There is a 
low concentration of analyte molecules present in the matrix, and this dilution helps to 
prevent the sample molecules from associating with each other to form complexes with 
masses too large for desorption and analysis.  The pulsed UV laser generates mostly 
singly-charged intact molecular ions, as well as dimers and doubly-charged molecular 
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ions (89,92,93).  This ionization method is not completely understood, although it is 
probable that multiple reactions are occurring in the MALDI plume (93). 
 Time-of-flight (TOF) mass analyzers are often coupled to MALDI ion sources.  
In a TOF spectrometer, ions are accelerated to a fixed kinetic energy by an electrical 
potential.  The velocity of the ions is proportional to (m/z)-1/2, where m/z is the mass to 
charge ratio of the analyte ions (91,94).  Ions then pass through a field-free region, 
where they are separated into groups of ions whose velocity is characteristic of their 
mass.  A detector at the end of the field-free region produces a signal as each ion group 
strikes it, thus creating a mass spectrum.  
 The signal detected in the mass spectrum is highly dependent on the choice of 
matrix (91,93). Derivatives of cinnamic acid, such as sinapinic, ferulic, and caffeic acids, 
have proven to work satisfactorily for a range of proteins (95).  Crystallization studies of 
sinapinic acid have shown that the protein molecule is incorporated into the crystal 
structure of the matrix (96). 
 Differing sample preparations can also affect the detected signal.  The thin-layer 
method has been shown to produce homogenous spots for analysis.  A spot of pure 
matrix is placed under the analyte and matrix sample.  The spot can be washed with cold 
water to remove any contaminants from the crystallized structure.  This method has 
increased sensitivity and resolution in comparison to other sample preparation methods 
(97). 
 MALDI-TOF-MS has been used successfully for the characterization of proteins.  
Complex protein mixtures can be elucidated because of the many singly-charged ions, 
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and high mass accuracy makes identification of individual proteins possible (91,98).  
Post-translational modifications, such as glycosylation and acetylation, can be easily 
detected with a MALDI-TOF-MS system (91,98).  There are some drawbacks to protein 
analysis via MALDI-TOF-MS, such as suppression effects in the mass spectrum and 
possible differences in ionization efficiencies in the sample mixture. 
 Apolipoprotein mixtures have been characterized using MALDI-TOF-MS.  HDL 
fractions have been analyzed for feasibility (99), as well as for characterization of novel 
isoforms of various apolipoproteins (100,101,102).  VLDL fractions have been analyzed 
and new isoforms of apo C-III detected as well as polymorphisms of the apolipoproteins 
(100,103).  Novel isoforms of apolipoproteins, believed to be products of methionine 
residue oxidation, have been detected in both VLDL and HDL fractions (100,104).  
Methionine residues in apo C-II and pro apo C-II are converted to either sulfoxides or 
sulfones, resulting in a mass shift of 16 or 32 Da respectively (100,101).  Apo A-I has 
also been shown to undergo methionine oxidation (104,105,106,107).  The detection of 
oxidation of apolipoproteins by MALDI-TOF MS has not been well established, 
however, so little more is known. 
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MATERIALS, INSTRUMENTATION, AND METHODS 
 
Materials 
Human Serum Collection 
 Serum samples were obtained by venipuncture into an 8 mL Vacuette treated 
with silica clotting activator and containing a separation gel (Greiner Bio-One, 
Kremsmuenster, Austria). 
 
Human Plasma Collection 
 Plasma samples were obtained by venopuncture into an 8 mL Vacuette treated 
with lithium heparin and containing a separation gel (Greiner Bio-One, Kremsmuenster, 
Austria).   
 
Sample Oxidation 
 Serum and plasma samples were oxidized using 2,2’-azobis-(2-amidinopropane) 
dihydrochloride (AAPH, 440914, Aldrich, Milwaukee, WI, USA) in eppendorf tubes 
(Eppendorf, Hamburg, Germany). 
 
Thiobarbituric Acid Reactive Substances (TBARS) Assay 
 Oxidized samples were mixed with thiobarbituric acid (TBA, T-5500, Sigma, St. 
Louis, MO, USA) as a 0.4% (w/w) solution in deionized water from a Milli-Q water 
purification system (Millipore, Bedford, MA, USA), and 0.5% (w/w) butylated 
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hydroxytoluene (BHT, B-1378, Sigma, St. Louis, MO, USA) in acetic acid (99.7%, 
AX0073-9). 
 
Separation of Lipoprotein Particle Classes by Single Spin Ultracentrifugation 
 A 20% (w/w) solution of cesium-bismuth-ethylenediaminetetracetic acid 
(EDTA) (CsBiY) in 0.02 M phosphate buffer (PB) was used as a density gradient for the 
separation of lipoprotein classes.  The CsBiY was synthesized in our laboratory 
following a published procedure (108).  The buffer was made from sodium phosphate 
monobasic (SX0710-1, EM Science, Gibbstown, NJ, USA) and dibasic (SX0715-1, EM 
Science, Gibbstown, NJ, USA) in a 1.6:1 ratio. 
 A 10% (w/v) solution of sodium-bismuth-EDTA (NaBiY) in water was also used 
as a density gradient.  NaBiY is commercially available (E086, TCI America, Portland, 
OR, USA). 
In either density gradient, serum and plasma samples were stained with N-(7-
nitrobenz-2-oxa-1,3-diazol-7-yl)-6-ceramide (NBD, N-1154, Molecular Probes, Eugene, 
OR, USA) as a 1 mg/mL or 2 mg/mL solution in dimethyl sufoxide (DMSO, 99.9%, 
MX1458-6 Burdick &Jackson, Muskegon, MI, USA) or with Nile Red (N-1142, 
Molecular Probes, Eugene, OR, USA) as a 1 mg/mL solution in DMSO. 
 
C18 Solid Phase Extraction, Desalting, and Delipidation 
 The proteins in VLDL, LDL, and HDL were delipidated and purified using a tC18 
Light cartridge (Sep-Pack, 36805, Waters, Milford, MA, USA).  Also used were 
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trifluoroacetic acid (TFA, T-6508, Sigma, St. Louis, MO, USA), and acetonitrile (ACN, 
99.8%, AX0145-1, EM Science, Gibbstown, NJ, USA). 
 
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry 
 Protein samples were prepared for MALDI-TOF-MS using sinapinic acid (98%, 
D-7927, Sigma, St. Louis, MO, USA) in methanol (99.8%, MX0475-1, EM Science, 
Gibbstown, NJ, USA) as a matrix.   
 
Instrumentation 
Serum and Plasma Collection 
 Serum and plasma were separated from red blood cells by a 3200 rpm 
centrifugation for 20 minutes at 4°C in a Compact II Centrifuge (Clay Adams Brand, 
Becton Dickinson, Franklin Lakes, NJ).  Serum and plasma samples were divided into 
aliquots and stored at -85°C in a Revco Elite Freezer (Fisher Scientific, Pittsburgh, PA, 
USA) until analysis. 
 
Sample Oxidation 
 Serum and plasma samples were oxidized by incubation at 37°C in an Isotemp 
Incubator (Model 5250, Fisher Scientific, Pittsburgh, PA, USA). 
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TBARS Assay 
 The TBARS assay constituents were incubated at 100°C in an Isotemp Vacuum 
Oven (Model 281, Fisher Scientific, Pittsburgh, PA, USA). Absorbance values were 
obtained on a µQuant Universal Microplate Spectrophotometer (Bio-tek Instruments, 
Inc., Winooski, VT, USA) using an acrylic 96 well UV-plate (Corning Costar, Acton, 
MA, USA). 
 
Separation of Lipoprotein Particle Classes by Single Spin Ultracentrifugation 
 The separation of lipoprotein classes was achieved in a Beckman Optima TLX 
tabletop ultracentrifuge (UC) using a 30° fixed angle TLA 129.2 rotor (Beckman 
Instruments, Fullerton, CA, USA).  Samples were placed in 1.5 mL open-top 
polycarbonate centrifuge tubes (Beckman Instruments, Fullerton, CA, USA).   
 
Imaging and Analysis of UC Tubes 
 Imaging of the UC tubes containing sample stained with NBD occurred using a 
Nikon Coolpix 5000 camera (Nikon, Inc., Melville, NY) mounted in a custom built 
fluorescence photography station.  In the system, the light source and camera were 
orthogonal to each other in order to minimize the amount of excitation light reaching the 
camera.  The light source was a 50W halogen lamp (14927, General Electric Co., 
Cleveland, OH, USA).  A hot mirror (46-452, Edmund Industrial Optics, Barrington, NJ, 
USA) and an excitation blue-pass glass filter (46-432, Edmund Industrial Optics, 
Barrington, NJ, USA) were placed between the light source and the sample chamber.  
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The camera was fitted with an emission dichroic Sybr Green filter (849 9246, Eastman 
Kodak, Rochester, NY, USA).  The filters were chosen so that there was essentially no 
overlap in their band pass regions (Figure 13). 
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Figure 13. Transmittance curves for excitation and emission filters used with NBD. 
 
 UC tubes containing sample stained with NR were imaged on a different system.  
A 3.3 megapixel color digital Firewire System (Leica DFC 300, TM060769, Optronics, 
Goleta, CA, USA) was mounted on a composite bread board (19”X23”, Technical 
Manufacturing Corporation, Peabody, MA, USA) orthogonal to a fiber-lite metal halide 
machine vision illuminator (MH-100, Dolan Jenner Industries, Lawrence, MA, USA).  
Both used mounts from Edmund Industrial Optics (Barrington, NJ, USA), as did a 
custom built tube holder.  The camera and light source were fitted with changeable 
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filters.  The light source had a 400 nm bandpass excitation filter (46-431, Edmund 
Industrial Optics, Barrington, NJ, USA) and the camera had a 590 nm longpass emission 
filter (46-063, Edmund Industrial Optics, Barrington, NJ, USA) (Figure 14).  
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Figure 14. Transmittance curves for excitation and emission filters used with NR. 
 
 With either photography station, OriginPro7 (Microcal Software, Inc., 
Northampton, MA, USA) operated on a 650 MHz Pentium III computer was used for 
data analysis. 
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Fraction Collection 
 In order to collect lipoprotein fractions after the centrifugation step, a scroll saw 
(Model 1672, 16-inches, 2-speed, Dremel) with a thin blade (0.254 mm wide) was used 
to cut the centrifuge tubes.  A custom brass template with built in micrometer assured 
accurate slicing.  Sawdust was pelleted out of the lipoprotein fraction using a Minispin 
Plus centrifuge (Eppendorf, Hamburg, Germany). 
 
Fluorescence Measurements 
 Fluorescence measurements were taken on a SLM Aminco Spectrofluorometer 
(Model 8100, Series 2, Spex, Jobin Yvon, Edison, NJ, USA).  Samples were analyzed in 
the same polycarbonate tubes used for ultracentrifugation, held in position by a custom 
built holder. 
 
C18 Solid Phase Extraction, Desalting, and Delipidation 
 For multiple analyses, a vacuum manifold (WAT200609, Waters, Milford, MA, 
USA) was used for cartridge delipidation and purification. 
 
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry 
 MALDI-TOF-MS analysis was done using a commercial Voyager DE STR, 
equipped with a 2 meter flight tube (Applied Biosystems, Inc., Foster City, CA, USA). 
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Methods 
Serum and Plasma Collection 
 All blood was taken from a normolipidemic subject following a 12 hour fast.  
Samples were collected via venopuncture at the Scott and White laboratory in College 
Station, TX.  Serum or plasma was separated from red blood cells by centrifugation for 
20 minutes at 3200 rpm at 4°C.  The supernatant was removed, aliquoted, and stored at -
85°C until analysis.   
 
Sample Oxidation 
 In order to oxidize the sample, serum or plasma was mixed with 750 mM AAPH 
for a final AAPH concentration of 50 mM, and incubated at 37°C for times varying 
between six and 24 hours in closed eppendorf tubes.  For 150 µL of serum, this equates 
to 10.7 µL of AAPH.  Some later studies used a final AAPH concentration of 24 mM 
(150 µL of serum plus 5 µL of AAPH). 
 
TBARS Assay 
 To measure the TBARS response, 50 µL of sample (oxidized or unoxidized 
serum or plasma) was mixed with 250 µL 0.4% (w/w) TBA solution in deionized water 
and 5µL 0.5% (w/w) BHT in acetic acid.  The samples were incubated at 100°C for 20 
minutes, and then pipetted into a 96-well plate.  The absorbance spectrum was read from 
500 to 600 nm, and an absorbance value read at 532 nm. 
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Separation of Lipoprotein Particle Classes by Single Spin Ultracentrifugation 
 The conventional method for separation of lipoprotein classes is density gradient 
centrifugation.  A novel density gradient, CsBiY, was used to generate a self-forming 
density gradient upon ultracentrifugation.  A 6 µL aliquot of serum was added to 590 µL 
of water, 600 µL 20% (w/w) CsBiY in 0.02 M PB, and 4 µL stain.  The stain was one of 
two fluorescent probes, 1 mg/mL NBD or NR in DMSO.  After complete mixing, 1 mL 
of sample was transferred to a clean ultracentrifuge tube.  The tube was centrifuged for 4 
hours 30 minutes at 120,000 rpm at 5°C. 
 NaBiY was also used as a density gradient.  A 6 µL aliquot of serum was added 
to 1100 µL of 10% (w/v) NaBiY in water, and 4 µL 1 mg/mL NBD or NR in DMSO.  
After complete mixing, 1 mL of sample was transferred to a clean ultracentrifuge tube.  
The tube was centrifuged for 6 hours at 120,000 rpm at 5°C.   
When more oxidized lipoprotein was necessary, a 60 µL aliquot of serum was 
added to 1100 µL of 10% (w/v) NaBiY in water, and 10 µL of 2 mg/mL NBD. 
Following complete mixing, 1 mL of sample was transferred to a clean ultracentrifuge 
tube, and was centrifuged for 6 hours at 120,000 rpm at 5°C.   
 
Imaging and Analysis of UC Tubes 
 Following the ultracentrifugation step, each tube was photographed.  The image 
was converted to a data file, and a density profile produced.  Figure 15 shows an 
example of a lipoprotein profile.    Profiles of unoxidized and oxidized samples were 
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compared, and the mean density of the LDL and HDL fractions calculated using a peak-
fitting program. 
 
Fraction Collection 
 Ultracentrifuge tubes were slowly frozen in liquid nitrogen following the UC 
spin and photography step.  Individual lipoprotein fractions were collected by cutting the 
frozen tubes at specific cut positions calculated from the points of minimum 
fluorescence on the density profile, as shown in Figure 15.  A thin blade scroll saw was 
utilized, as well as a custom built tube holder with micrometer to assure accurate cutting 
positions. 
 Following cutting, each fraction was centrifuged for 3 minutes at 7,000 g in order 
to remove any particulates remaining in the sample after the cutting step.   
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Figure 15. Lipoprotein density profile. 
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Fluorescence Measurements 
 For fluorescent analysis, fractions were placed in clean UC tubes.  A custom built 
tube holder held the UC tubes in position in the spectrofluorometer.  Emission and 
excitation scans were run on each sample.  For samples stained with NBD, excitation 
scans were performed with the emission wavelength set at 536 nm, and emission scans 
done with the excitation wavelength of 466 nm.  For samples stained with NR, excitation 
scans were performed with an emission wavelength set at 610, and emission scans done 
with an excitation wavelength of 535 nm. 
 
C18 Solid Phase Extraction, Desalting, and Delipidation 
 A solid phase extraction cartridge was utilized to separate the apolipoproteins 
from the lipids in the lipoprotein particles.  This delipidation process was based on a 
published method (109).  The cartridge was first conditioned dropwise with 5 mL of 
0.1% (v/v) TFA in acetonitrile, with no air being allowed to enter the cartridge.  Next, 
the cartridge was conditioned dropwise with 5 mL 0.1% (v/v) TFA in water, again with 
no air being allowed to enter.   
Samples were prepared for delipidation by adding 1% TFA in water until the 
final TFA concentration was 0.1%.  Each sample was loaded slowly onto the cartridge.  
Following sample loading, the cartridge was rinsed with 5 mL 0.1% (v/v) TFA in 
water in order to remove salts and contaminations from the UC spin.  Air was pushed 
through the cartridge to remove any remaining liquid.  Finally, proteins were eluted in 
50 µL aliquots of 0.1% TFA in acetonitrile.  The second, third, and fourth aliquots, 
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which contained the majority of the apolipoproteins, were collected and combined for 
further analysis. 
 
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry 
 Protein samples were analyzed using a commercial MALDI-TOF mass 
spectrometer in the positive, linear mode.  A thin-layer sample preparation method was 
used.  A 0.5 µL aliquot of 35 mg/mL sinapinic acid was deposited on the plate and 
allowed to dry.  Samples were prepared by mixing 2 µL of the eluted fraction with 3 µL 
of 25 mg/mL sinapinic acid and 6 µL deionized water.  A 0.5 µL aliquot of the sample 
mixture was applied to the plate, and allowed to dry.  Three 2 µL cold water rinses of the 
sample spot cleaned away any residual salt buildup.  Mass spectra were calibrated using 
apolipoprotein A-I and apolipoprotein C-I. 
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RESULTS AND DISCUSSION 
 
Optimization of in Vitro Oxidation of Lipoproteins as Monitored by the TBARS 
Assay 
 The first phase of this research was the investigation of the oxidation of 
lipoproteins.  2,2’-azobis-(2-amidinopropane) dihydrochloride (AAPH) was chosen as 
the oxidation initiator because of its frequent use in previous, well characterized, 
reproducible, lipoprotein oxidation studies. 
 The volume of serum needed for oxidation was considered.  Literature cites large 
volumes of serum used for in vitro oxidation, up to 7 mL (53).  A direct scale down 
study was carried out in order to adapt the method to a lower volume of 700 µL of 
serum.  It was found that the high volume was unnecessary for the analyses following 
the oxidation step.  Further experimentation showed that the volume of serum oxidized 
was directly proportional to the extent of oxidation when the AAPH concentration was 
held constant.  In this study, the unoxidized sample was not incubated, but kept frozen at 
-85°C until analysis.  Figure 16 illustrates the increase in TBARS response to decreasing 
serum volumes.  Table 3 shows the TBARS response at 532 nm demonstrating this 
proportionality.  Increased oxidation in lesser volumes is believed to be due to the 
diffusion control process.  Smaller volumes allow for more diffusion and interaction to 
occur between particles, including the radicals initiated by AAPH. 
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Figure 16. TBARS response to varying serum volumes with constant AAPH 
concentration.  Oxidizing conditions were varying volumes of serum and 50 mM AAPH 
for 24 hours.  Unoxidizing conditions were storage at -85°C. 
 
 
Table 3. TBARS response to varying serum volume for oxidation, blanked with 
unoxidized serum.  Conditions identical to those in Figure 16. 
 
Volume oxidized serum (µL) Absorbance at 532 nm 
100 µL serum 0.506 
250 µL serum 0.390 
400 µL serum 0.378 
600 µL serum 0.346 
 
 
 Once the volume of serum for oxidation was chosen, the incubation time at 37°C 
necessary to perceive oxidation was examined.  For 100 µL of serum and an AAPH 
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concentration of 50 mM, minimal oxidation took place in the first hour of incubation.  
Figure 17 illustrates TBARS response over ten hours.  After approximately five hours, 
the concentration of TBARS in the sample increased at a much slower rate (Figure 18).  
It was concluded that six hours is a satisfactory incubation time for the measurable 
oxidation of 100 µL of serum.  Sample-to-sample relative standard deviation of the 
oxidation procedure was calculated to be 16.7% (n = 10), based on the TBARS assay. 
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Figure 17. TBARS response to varying oxidation times.  Oxidizing conditions were 100 
µL of serum and 50 mM AAPH for varying times.  Unoxidizing conditions were storage 
at -85°C. 
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Figure 18. TBARS response to varying oxidation times, blanked with unoxidized serum.  
Conditions identical to those in Figure 17. 
 
 
 
 Initial estimates of how much oxidized serum was necessary for complete 
analysis were too low.  Therefore, the volume of serum used in the oxidation step was 
increased to 150 µL.  In order to increase the extent of oxidation of the lipoprotein 
particles, incubation time with AAPH was increased to 15 hours. Data confirmed that 
oxidation continued after 15 hours, indicating that the particle was not completely 
oxidized at the 15 hour time point.   
 
TBARS Assay 
 During the development of the oxidation procedure it was necessary to adjust the 
TBARS assay protocol as well.  Multiple procedures have been published for the 
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TBARS assay.   For this research, however, a new TBARS procedure requiring only 50 
µL of sample was developed.   
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Figure 19. Absorbance vs wavelength of TBARS for varying oxidation times.  Oxidizing 
conditions were 100 µL of serum and 50 mM AAPH for varying times.   
 
 
 
A set of UV/Vis spectra from the TBARS assay over time of oxidation was 
recorded from 500 to 600 nm.  A peak centered at 540 nm became more intense with 
time of oxidation (Figure 19).  Literature cites the maximum of the TBARS 
chromophore at 532 nm; however experimentation in this study showed that the 
maximum lies at 540 nm.  An experiment was performed to determine if absorbance 
measurements differed significantly between 532 nm and 540 nm.  Results showed that 
 46 
 
the two were very comparable; therefore, further measurements were obtained at 532 nm 
to comply with convention.  Sample-to-sample standard deviation of absorbance 
measurements at 532 nm following the TBARS assay was calculated to be 2.57% (n = 
5). Subsequent TBARS assays were performed as outlined in the Methods section (page 
34).   
 
Separation and Profiling of Lipoprotein Classes by Density Gradient 
Ultracentrifugation:  Influence of Oxidation 
  
 The TBARS assay has many weaknesses, particularly specificity for elucidating 
lipid oxidation (60), and it was the goal of this research to develop a new detection 
technique for the susceptibility of lipoprotein oxidation.  Our laboratory developed a 
density profiling method that is sensitive to slight shifts in the buoyant density of 
lipoprotein particles.  Since oxidation of lipoproteins can change their properties, 
particularly density (17,40), the ultracentrifuge method was attractive for monitoring 
lipoprotein oxidation.   
As oxidation occurs, low molecular weight oxidation products are formed in the 
lipid core and separate from the lipoprotein particle (17,37,40), causing a significant 
increase in buoyant density.  These changes in the lipid core by exposure to AAPH were 
verified using the profiling procedure following the ultracentrifuge spin.  Figure 20, 
Figure 21, and Figure 22 demonstrate that the shift in buoyant density over oxidation 
time closely shadows the response from the TBARS assay for lipid oxidation, indicating 
the density shift is indeed due to oxidation of the lipoprotein particles. 
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Figure 20. TBARS response over oxidation time. Oxidizing conditions were 700 µL of 
serum and 50 mM AAPH for varying times.  Unoxidizing conditions were storage at      
-85°C. 
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Figure 21. Buoyant density shift over oxidation time.  Conditions identical to those in 
Figure 20.  Ultracentrifuge conditions were NaBiY and NBD. 
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Figure 22. Comparison of TBARS response and LDL density shift.  Conditions identical 
to those in Figure 20 and Figure 21. 
 
 
As the incubation time increased, the mean buoyant density of the LDL particle 
also increased, indicating the loss of lipids and a higher protein to lipid ratio.  LDL mean 
buoyant denisty shifted from 1.033 kg/L in the unoxidized sample to 1.043 kg/L in the 
24 hour oxidized sample, a change of 0.010 kg/L (Figure 21). HDL also showed a shift 
in density as a function of oxidation time, from 1.088 kg/L in the unoxidized sample to 
1.096 kg/L in the 24 hour oxidized sample.  The change was 0.008 kg/L.  The density 
gradient in the HDL is much steeper, and less movement is expected for an identical 
change in density.  While peaks shift to a higher density, peak shape stays constant. This 
indicates that the entire population of particles is being oxidatively modified.   
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Influence of Fluorescent Probe on Lipoprotein Profiles 
 In the course of this research, two fluorescent probes were examined for their 
ability to document density profiles of individual lipoprotein classes.  The first, 7-
nitrobenz-2-oxa-1,3-diazol-4-yl ceramide (NBD), was highly successful in a CsBiY 
density gradient, as previously discussed (69), as well as in NaBiY.  The NBD profile 
for unoxidizing and oxidizing conditions are shown in Figure 23.   
Lower quality profiles were produced using the second probe, Nile Red (NR).  In 
order to efficiently excite NR at its excitation wavelength, new filters were employed in 
the digital imaging system.  The properties of these excitation and emission filters 
(Figure 14) are not ideal for the excitation and emission spectra of NR.  The excitation 
filter does not completely overlap the excitation range of NR, resulting in less excitation 
energy reaching the fluorophore.  This creates a non-zero baseline and contributes to the 
decrease in fluorescence intensity (Figure 24).  Oxidized lipoproteins showed a 
significant density shift when stained with NBD (Figure 23), but the shift was 
considerably smaller when the same sample was stained with NR, an unexpected result.  
The mechanism of lipoprotein staining is, in general, not well understood.  NR stains the 
core lipids of lipoproteins, which are the first to be oxidized (84).  It is hypothesized that 
as oxidation occurs and alters the core of the lipoprotein particle, NR no longer has the 
same binding affinity.  It stains the least oxidized lipoproteins preferentially, limiting the 
amount of buoyant density shift seen in the density profile.  
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Figure 23. Density profile of lipoproteins stained with NBD in NaBiY.  Oxidizing 
conditions were 100 µL of serum and 50 mM AAPH for six hours.  Unoxidizing 
conditions were incubation at 37°C for six hours.  Ultracentrifuge conditions were 
NaBiY and NBD. 
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Figure 24. Density profile of lipoproteins stained with NR in NaBiY.  Oxidizing and 
unoxidizing conditions were identical to those in Figure 23.  Ultracentrifuge conditions 
were NaBiY and NR. 
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Influence of CsBiY vs NaBiY on Lipoprotein Profiles 
NR does not fluoresce as intensely when in the presence of the NaBiY density 
gradient.  Compared to the CsBiY, NaBiY resulted in a three-fold decrease in 
fluorescent intensity (Figure 25 and Figure 26).  It is unclear why the fluorescence 
intensity is higher with CsBiY than with NaBiY.  Similar studies with NBD exhibited a 
decrease in fluorescence intensity, however only a two-fold decrease was observed.  The 
difference between NR and NBD properties in CsBiY and NaBiY is most likely due to 
their binding sites on the lipoprotein.  NR binds in the hydrophobic lipid core, while 
NBD stays in the hydrophilic surface.   
It can be hypothesized that the main difference between CsBiY and NaBiY is the 
sizes of the positively charged ions:  Cesium ions (mw = 132.9) are much bigger than 
sodium ions (mw = 23.0).  Lipoprotein particles are negatively charged, and the 
positively charged cesium and sodium ions are therefore attracted to it.  Since the 
sodium ions are significantly smaller, they could pack more efficiently and shield the 
lipoprotein from interacting with the fluorescent probe.  Cesium ions are larger, and 
cannot exert the same blocking action. 
The loss of fluorescence intensity resulted in decreased detail in the lipoprotein 
peaks in the profiles.  As shown in Figure 25, the LDL and HDL peaks are wide and not 
well resolved.  It is difficult to determine where the LDL fraction ends and HDL begins, 
and there is no evidence of the detail that can be seen with NR in CsBiY (Figure 26), or 
with NBD in NaBiY (Figure 23).  NaBiY was the medium of choice because it is 
commercially available and gives comparable profiles to CsBiY when NBD is used.  
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The combination of NaBiY and NBD was determined to be a more efficient system for 
lipoprotein profiling than NaBiY and NR.  Therefore, NBD was used for further density 
shift experiments.   
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Figure 25. Density profile of unoxidized lipoproteins stained with NR in NaBiY. 
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Figure 26. Density profile of unoxidized lipoproteins stained with NR in CsBiY. 
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Influence of Serum vs Plasma on Lipoprotein Profiles 
 Human serum and plasma were examined, as they are both used in lipoprotein 
oxidation studies reported in literature, to determine whether serum or plasma should be 
used in the study.  In time-dependent oxidation studies, density profiles of the two 
sample types were almost identical (Figure 27 and Figure 28).  Serum was chosen for 
further studies in order to mainstream the procedures, as well as to provide consistency 
with previous results obtained in our laboratory. 
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Figure 27. Density profile of serum.  Oxidizing conditions were 650 µL of serum and 50 
mM AAPH for 24 hours.  Unoxidizing conditions were storage at -85°C for 24 hours.  
Ultracentrifuge conditions were CsBiY and NBD. 
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Figure 28. Density profile of plasma. Oxidizing conditions were 650 µL of serum and 50 
mM AAPH for 24 hours.  Unoxidizing conditions were storage at -85°C for 24 hours.  
Ultracentrifuge conditions were CsBiY and NBD. 
 
Influence of 37°C Incubation on the Lipoprotein Profiles of Control Samples 
 Two kinds of unoxidized control samples were studied.  The first was incubated 
at 37°C for the same amount of time as the oxidized sample being studied.  No AAPH 
was added, and presumably no oxidation took place.  The second control was kept at  
-85°C during the incubation step for the oxidized samples, and then thawed for analysis.  
For a 24 hour incubation the TBARS assay showed little difference between the two 
controls (Figure 29), indicating no oxidation took place without AAPH.  The density 
profiles, however, were distinctly different (Figure 30).  A hypothesis is that during 
incubation, surface lipids are shed from the lipoprotein particle, thereby changing its 
density.  TBARS response would not change, as the freed lipids are unoxidized. 
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Figure 29. TBARS of non-incubated and incubated controls. Oxidizing conditions were 
650 µL of serum and 50 mM AAPH for 24 hours.  Unoxidizing conditions were storage 
at -85°C or incubation at 37°C for 24 hours.   
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Figure 30. Density profiles of non-incubated and incubated controls in CsBiY. 
Conditions identical to those in Figure 29. Ultracentrifuge conditions were CsBiY and 
NBD. 
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 When sample volume was decreased to 150 µL and incubation time decreased to 
15 hours, the density profiles for the two controls showed no mean density shifts in the 
lipoprotein particles (Figure 31).  No process in the incubation step was affecting the 
density profile. 
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Figure 31.  Density profiles of non-incubated and incubated controls in NaBiY.  
Unoxidizing conditions were storage of 150 µL of serum at -85°C or incubation at 37°C 
for 15 hours.  Ultracentrifuge conditions were NaBiY and NBD. 
 
 
Influence of Serum Volume on Lipoprotein Profiles 
 The influence of volume of serum used in the ultracentrifuge step was 
investigated by examining 6 µL and 60 µL samples.  Both produced acceptable 
lipoprotein profiles; however, the 60 µL volume was shown to give a more intense 
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fluorescence signal and have higher sample-to-sample reproducibility.  Based on this 
result, further work was carried out using the 60 µL serum sample. 
 
Fluorescent Probe Analysis 
 Both fluorescent probes used in the density profiling step are sensitive to their 
microenvironment.  As the polarity of their surroundings increase, the absorption and 
emission maxima of the probes shift to a higher wavelength.  The use of this shift for the 
detection of oxidation was investigated using UC fractions. 
NBD stained lipoproteins exhibited no shift in the absorption or emission 
between oxidized and unoxidized serum samples in either the LDL (Figure 32) or HDL 
(data not shown).  This observation could be due to the fact that the NBD stain is not 
sensitive to minor environmental changes such as oxidation.  The NBD resides on the 
surface of the lipoprotein, in the hydrophilic domain (79,80), whose constituents are only 
oxidized after the lipid core has been completely oxidized (110).  The fact that no shift in 
wavelength maxima was detected may be due to the location of the NBD fluorophore in 
the lipoprotein particle. 
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Figure 32. Absorption and emission spectra for NBD labeled LDL. 
 
 
 A shift was detected in both absorbance and emission peaks for the NR stained 
LDL and HDL. The LDL emission peak shifted from 608 nm in the unoxidized sample 
to 616 nm in the oxidized sample, and the excitation peak shifted from 505 nm to 526 
nm (Figure 33).  HDL fractions did not exhibit shifts as large as those seen in LDL.  
Emission shifted from 621 nm to 622 nm and excitation from 523 to 529 (Figure 34).   
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Figure 33. Absorption and emission spectra for NR labeled LDL. 
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Figure 34. Absorption and emission spectra for NR labeled HDL. 
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 An interesting result was that NR had different absorption and emssion peak 
maxima for unoxidized HDL and LDL, reflecting the different microenvironments of the 
lipoprotein particles.  Both the absorption and emission peaks for the HDL were 
centered at higher wavelengths than those for LDL, indicating a more polar environment 
in the HDL particle.  This observation makes sense due to the fact that LDL contains a 
higher proportion of non-polar lipids than does HDL. 
 In the excitation spectra, each LDL and HDL peak has a shoulder at 475 nm.  
Because the shoulder appears in both oxidized and unoxidized samples, it was assumed 
not to be a product of the oxidation step.  The exact identity of this chromophore is 
unclear, however it could be used as an internal calibrant for fluorescence measurements 
due to its consistent presence. 
While shifts in the absorption and emission spectra due to oxidation were 
observed, the most sensitive markers for oxidation were found to be the density profile 
and MALDI-TOF-MS of the HDL apolipoproteins.     
  
MALDI-TOF-MS 
 As lipoproteins undergo oxidation, lipid moieties are changed as well as protein 
moieties.  Changes in lipoprotein lipid content are observed by mean density shifts in the 
density profile, which is especially useful for LDL modifications.  HDL consists of 
many lipoprotein particles whose oxidative modifications could be studied using 
MALDI-TOF-MS.  The apolipoproteins in HDL are of mass ranges suitable for MALDI 
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analysis, and the method is sensitive enough to elucidate small mass changes due to 
oxidative processes.  
Two control samples were analyzed, one not incubated (Figure 35), and the other 
incubated at 37°C for 15 hours (Figure 36).  The only difference between the two spectra 
was the appearance of a truncated isoform of SAA4 (SAA4’’’) in the incubated sample.  
Addition of AAPH without incubation (no oxidation) showed no significant differences 
in peak appearance or m/z values compared to the unoxidized samples (data not shown).  
Thus, any changes in the spectra could be attributed to either incubation or AAPH 
oxidation.  Furthermore, two samples of varying levels of oxidation were studied.  The 
lesser oxidized sample was incubated with 24 mM AAPH (Figure 37), and the more 
oxidized sample incubated with 50 mM AAPH (Figure 38) for the same 15 hour period. 
The control samples were very similar to previously recorded spectra of 
unoxidized HDL (102).  Several significant changes were easily observed in the oxidized 
spectra.  In the lesser oxidized sample, a new peak was formed at 13870 m/z.  The 
isoforms of SAA4 shifted in distribution.  A second new peak was formed 800 m/z 
higher than apo A-I, and the A-I dimer completely disappeared.  The more oxidized 
sample illustrated all these changes, as well as the apo C-I and apo C-I’ peaks splitting 
into doublets. 
Observed m/z values for oxidized and unoxidized samples, as well as calculated 
values, can be found in Table 4.   Table 5 summarizes the differences between oxidized 
and unoxidized spectra. 
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Figure 35. MALDI mass spectrum of apolipoproteins from non-incubated HDL. 
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Figure 36. MALDI mass spectrum of apolipoproteins from incubated HDL. 
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Figure 37. MALDI mass spectrum of HDL oxidized with 24 mM AAPH for 15 hours. 
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Figure 38. MALDI mass spectrum of HDL oxidized with 50 mM AAPH for 15 hours. 
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Table 4. Identification of peaks in mass spectra of HDL fractions.   
Average 
Massunox 
Average 
Massox 
MW calc Code Identification 
6426.43 6435.94 6432.40 C-I’ Apo C-I minus N-Thr-Pro 
- 6448.35 6448.40 C-I’ox Oxidized Apo C-I’, + 16 Da 
6630.60 6630.60 6630.60 C-I Apo C-I 
- 6646.04 6646.60 C-Iox Oxidized apo C-I, + 16 Da 
6844.85 6831.87 6836.80 q Apo C-I + 206 Da adduct 
8208.44 - 8204.10 C-II Apo C-II 
- 8635.25 8626.85 A-II’2+ Apo A-II minus C-Gln-Gln, z = 2 
8684.26 8699.16 8681.80 A-II’monomer Apo A-IImonomer minus C-Gln 
8809.11 8819.30 8809.90 A-IImonomer Single chain apo A-II 
8870.70 8883.13 - x Unidentified 
8913.15 8922.81 8914.90 pro C-II pro Apo C-II 
9018.55 - - 16 A-IImonomer + 209 Da adduct 
9132.62 9143.37 9130.00 C-III0,Glyc Galβ1,3GalNAc-O-C-III0 
- 9288.21 9279.10 C-III1’’ Apo C-III1 minus C-Ala-Ala 
9363.28 9360.75 9350.20 C-III1’ Apo C-III1 minus C-Ala 
9419.65 9427.84 9421.30 C-III1 Apo C-III1 
9580.81 9572.29 9570.40 C-III2’’ Apo C-III2 minus C-Ala-Ala 
9641.56 9636.52 9641.50 C-III2’ Apo C-III2 minus C-Ala 
9718.39 - 9712.60 C-III2 Apo C-III2 
12451.56 12456.41 12443.60 SAA4’’’ SAA4 minus C-Lys-Lys-Tyr 
12571.28 12587.36 12571.80 SAA4’’ SAA4 minus C-Lys-Tyr 
12857.56 12862.24 12863.20 SAA4 SAA4 
- 13869.73 - ox1 Unidentified oxidation product 
- 13941.05 13881.20 A-I’’2+ Apo A-I minus C-Thr-Gln 
14033.73 14039.03 14039.30 A-I2+ Apo A-I, z = 2 
14139.58 14153.13 14137.40 A-I+2add2+ Apo A-I + 2-98 Da, z = 2 
- 14465.33 14480.80 pro A-I2+ pro Apo A-I, z = 2 
17146.31 17135.42 17125.60 A-II’’ Apo A-II minus 2-C-Gln 
17254.61 17258.93 17253.70 A-II’ Apo A-II minus C-Gln 
17381.78 17386.67 17379.80 A-II Apo A-II 
17596.33 17599.41 - 51 Unidentified 
28078.60 28078.60 28078.60 A-I Apo A-I 
- 28851.35 - A-Iox Unidentified (A-I ox peak,+800) 
- 33353.29 33000.00 HSA2+ Albumin, z = 2 
56265.90 - 56157.20 A-Idimer A-I dimer 
- 66680.99 66000.00 HSA Albumin 
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Table 5. Differences in unoxidized and oxidized MALDI-TOF mass spectra. 
• Apo C-I’ and apo C-I form new peaks, 16 Da higher than the parent 
• 10 m/z increase in proapo C-II 
• 11 m/z increase in apo C-III0,Gly 
• Isoform distribution of SAA4, SAA4’’, and SAA4’’’ reverses in 
intensity 
• 16 m/z increase in SAA4’’ 
• 10 m/z increase in apo A-IImonomer 
• Apo A-I forms a new peak, 800 Da higher than the parent 
• New peak at 13870 Da 
 
 
The mass spectrum for an oxidized sample is significantly different from one for 
an unoxidized sample.   Apolipoprotein C-I (apo C-I) is involved in the activation of 
lecithin:cholesterol acyltransferase (LCAT) (111,112), an enzyme whose main function 
is the conversion of cholesterol to cholesterol ester (113). A truncated form of apo C-I, 
apo C-I’, has been identified as lacking two amino acid residues from the N-terminus as 
determined by MALDI-TOF-MS (114).   Apo C-I’ and C-I appeared as singlets in both 
unoxidized spectra as well as the least oxidized sample.  However, after further 
oxidation, both the apo C-I’ and apo C-I appeared as doublets differing in m/z by 16 Da.  
This change is expected due to the conversion of the protein’s single methionine residue 
to a sulfoxide.   
Apolipoprotein C-II (apo C-II) exists as two isoforms, mature apo C-II and 
proapo C-II (114).  This protein activates lipoprotein lipase (115,116), which catalyzes 
the hydrolysis of triglycerides (117).  Apo C-II did not exhibit any changes upon 
oxidation; however the molecular weight of proapo C-II increased by 10 m/z units.   
 68 
 
The region from 8500 to 10,000 m/z changed significantly dependent on 
oxidation.  An increased number of peaks are present as well as a higher baseline, 
indicating the probable presence of an increased number of ion species in that region. 
Apolipoprotein C-III (apo C-III) plays a significant role in triglyceride 
metabolism (118).  Apo C-III is found in serum as three isoforms, apo C-IIIo, apo C-III1, 
and apo C-III2, differentiated by their degree of sialylation (118).  Following oxidation, 
the C-III0,Gly peak appeared at a m/z ratio 11 Da higher than the unoxidized samples.  No 
change was observed in the other apo C-IIIs. 
 Serum amyloid A (SAA) is an acute-phase protein of unknown function that 
exists in six isoforms (119,120).  SAA4 is found in normal serum (121), and has three 
distinct isoforms, SAA4’’’, SAA4’’, and SAA4 (102).  In unoxidized serum, the most 
dominant peak is SAA4, followed by the truncated forms SAA’’4 and SAA’’’4.  In the 
oxidized state, SAA’’’4 is the dominant peak, followed by SAA’’4 and SAA4.  This 
reversal of isoform dominance in the mass spectrum implies that oxidation may 
contribute to the shedding of amino acids from intact SAA4.  Another interesting note is 
that the SAA’’4 m/z increases by 16 from the unoxidized to the oxidized samples.  There 
are two methionine residues in SAA, and the m/z change could be due to sulfoxide 
formation. 
 Apolipoprotein A-II (apo A-II) is important to the structure of lipoproteins due to 
its lipid binding characteristics (118).  Apo A-II exerts a negative influence on reverse 
cholesterol transport, promoting the development of atherosclerosis (111,122,123).  In 
serum, apo A-II exists as a dimer, joined by a disulfide bond.  Some oxidation methods, 
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such as performic acid oxidation, break this bond, resulting in a complete loss of the apo 
A-II dimer peaks in the mass spectrum (100,101).  It was found that AAPH oxidation, 
however, does not break the disulfide link because peaks are present at the m/z for the 
A-II dimers.  Peaks are also located at the m/z for apo A-II monomer in both unoxidized 
and oxidized samples.  Oxidized samples show no doublet structure; however the m/z 
ratio for the apo A-II monomer is 10 m/z units higher than the unoxidized samples. 
Apolipoprotein A-I (apo A-I) is the main protein in HDL, and is an important 
structural component of lipoproteins (118).  Apo A-I is released into serum in a non-
mature state (proapo A-I), followed by cleavage of six amino acid residues to form the 
mature protein.  One of the major functions of apo A-I is the activation of LCAT (111).  
Apo A-I in unoxidized samples is observed as a singlet, but in oxidized samples it 
appears as a wide doublet, differing by a m/z of ~800 Da.  The exact nature of the 
modifications that occur to the apo A-I molecule during oxidation are not yet known.  
Another new peak is observed 169 m/z less than the apo A-I2+ peak.  Apo A-I2+ does not 
exist in serum; it is only present as an ion during the MALDI process. This new peak 
cannot be an oxidized form of apo A-I2+; however its identity is unknown. 
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CLINICAL APPLICATION 
 
 The methods developed in this research were applied to a pilot clinical study 
involving the role of California grapes as a source of dietary antioxidants.  Initial 
scientific interest in grapes stemmed from the French Paradox, an epidemiological study 
that found certain populations in France to have a high intake of saturated fats and 
relatively high plasma cholesterol, yet a low coronary heart disease mortality rate (124).  
This paradox has been partially attributed to a routine consumption of wine.  Phenolic 
substances in grapes act as potent antioxidants.  However the phenolic profile of wine 
differs from that of fresh grapes, as the grape crushing step and wine fermentation and 
aging cause significant changes in phenolic composition.  Table grapes, or grapes meant 
to be consumed fresh, have also been shown to significantly inhibit LDL oxidation in 
vitro (125,126).  The California Table Grape Commission has developed a freeze-dried 
grape powder that conserves the integrity of biologically active compounds found in 
fresh grapes.  This powder can be used for in vivo or in vitro studies on the antioxidant 
effects of grape phenolic compounds.  
 A volunteer ate foods low in phenolic compounds for 24 hours followed by a 12 
hour fast.   A baseline blood sample was drawn, followed by the consumption of the 
equivalent of five servings of table grapes in a freeze-dried powder provided by the 
California Table Grape Commission.  Blood was drawn each hour for five hours 
following grape consumption.   
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 The six samples were oxidized with AAPH and separated using the 
ultracentrifugation spin with fluorescent NBD stain.  A control that remained frozen 
during the oxidation step was also included.  Density profiles were constructed for each 
sample, and mean buoyant density values for LDL and HDL were determined using a 
peak-fitting program.  HDL fractions were isolated by cutting the tube at positions 
determined by the minima between classes.  Apolipoproteins were purified by tC18 Light 
cartridge delipidation, and MALDI-TOF-MS analysis was performed.  Figure 39 
through Figure 52 show the density profiles and MALDI spectra for the samples.  Mean 
density values and tube coordinates are indicated in the profiles 
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Figure 39. Density profile of control sample. 
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Figure 40. Density profile of baseline sample. 
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Figure 41. Density profile of one hour sample. 
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Figure 42. Density profile of two hour sample. 
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Figure 43. Density profile of three hour sample. 
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Figure 44. Density profile of four hour sample. 
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Figure 45. Density profile of five hour sample. 
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Figure 46. MALDI-TOF analysis of control sample. 
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Figure 47. MALDI-TOF analysis of baseline sample. 
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Figure 48. MALDI-TOF analysis of one hour sample. 
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Figure 49. MALDI-TOF analysis of two hour sample. 
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Figure 50. MALDI-TOF analysis of three hour sample. 
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Figure 51. MALDI-TOF analysis of four hour sample. 
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Figure 52. MALDI-TOF analysis of five hour sample.
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 As expected, dietary grape intake affected the density profile.  All oxidized 
samples showed an increase in mean buoyant density of LDL compared to the control.  
The baseline sample showed the largest increase (Figure 53), which was expected 
because the sample contained no antioxidants.   
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Figure 53. Density profiles as affected by grape consumption.  
 
 
 
The one hour serum sample exhibited apparent effects of antioxidants.  The LDL 
density did not shift from the control position as much as in the baseline sample (Figure 
53).  In the two hour sample, the LDL mean density increased from that observed with 
the one hour sample.  This effect is most likely due to the antioxidants being cleared 
from the bloodstream over time (127).  Three and four hour samples had continuing 
increasing mean densities but did not reach the level of the baseline sample.  The 
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antioxidants were expected to have continued to clear from the bloodstream leaving only 
low concentrations.   
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Figure 54. Shift in LDL mean density after grape consumption. 
 
 
 
 In the five hour sample, the LDL mean density shifted less than any other sample 
(Figure 54).  This observation was unexpected due to the belief that the antioxidants 
from the grape would clear the bloodstream, and shifts in LDL density would be equal to 
that seen in the baseline sample.  Due to this unexpected density shift in the five hour 
sample, the oxidation and ultracentrifugation steps were repeated to verify the results.  
Because it is known that grapes contain multiple types of antioxidant molecules, a 
hypothesis to explain the small LDL density shift five hours after grape intake would be 
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that the different antioxidants protect at different time intervals.  Initial protection begins 
immediately, as evidenced by the decreased LDL density shift in the one hour sample.  
After approximately four hours, a secondary antioxidant mechanism begins protection. 
This secondary protector is more efficient, as the LDL density shift is smaller than that 
seen with the one hour sample.   
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Figure 55. Shift in HDL mean density after grape consumption. 
 
 
 Shifts in HDL mean buoyant density showed similar trends (Figure 55).  The 
baseline sample exhibited a large shift in density, and the one hour sample a smaller 
shift.  The two and three hour samples showed increasingly larger density shifts.  
However, smaller density shifts were observed in the four and five hour samples, similar 
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to the five hour LDL sample.  The same hypothesis can be used to explain this 
phenomenon in the HDL as in the LDL. 
 As was noted in previous AAPH oxidation studies, the shapes of the LDL and 
HDL density peaks do not change following oxidation.  This similarity suggests that the 
antioxidants from the grape powder protect the entire population of lipoprotein particles. 
 MALDI-TOF-MS analysis of the oxidized and unoxidized samples reaffirmed 
the conclusion that MS is a useful tool in oxidized lipoprotein analysis.  In addition to 
the changes noted in the method development section, a new peak was observed at 
approximately 50000 Da in four of the oxidized samples (labeled ox2).  It is unclear what 
oxidative process forms this species. 
In order to determine if the changes in the mass spectra were proportional to 
hypothesized level of oxidation, peak area ratios were examined.  The area of peaks in 
the mass spectra are automatically calculated in the software on the mass spectrometer.  
Peak area ratios of major proteins that show oxidative modifications were calculated and 
are shown in Table 6.   
 
Table 6. Summary of peak ratios. 
Ratio Control Baseline 1 hour 2 hour 3 hour 4 hour 5 hour 
C-I’/C-I’ox - 0.337 0.429 - .526 0.680 1.037 
C-I/C-Iox - 0.689 0.928 0.398 18.549 0.363 1.387 
SAA4’’’/SAA4’’ 0.468 7.356 9.756 2.523 22.123 9.904 2.418 
SAA4’’’/SAA4 0.027 53.613 5.588 9.644 9.520 24.242 2.221 
SAA4’’/SAA4 0.057 7.2884 0.573 3.822 0.430 2.448 0.919 
A-I/new peak - 0.467 10.555 5.467 1.578 2.650 6.014 
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None of the calculated ratios demonstrated a proportionality to the hypothesized 
level of oxidation of the sample.  Further studies need to be done with more samples to 
determine if any peak area ratio is significantly changed over the oxidative process. 
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SUMMARY AND CONCLUSIONS 
 
 The main objective of this research was to develop a protocol for in vitro 
oxidation of human lipoproteins, and to monitor the oxidation with novel detection 
methods.  Density gradient ultracentrifugation and MALDI-TOF-MS were the analytical 
techniques chosen for the oxidation studies. 
 Oxidation of human serum was performed using AAPH, a free radical initiator.  
A volume studying indicated that oxidation efficiency was higher in smaller volumes of 
sample.  For 100 µL of sample, a time study was run to determine that six hours was a 
satisfactory incubation time for measurable oxidation.   
 All oxidation studies were monitored using the TBARS assay.  In order to 
accommodate small sample volumes, a new procedure was developed that required only 
50 µL of sample.  Using this new protocol, it was determined that increasing incubation 
time does in fact increase the TBARS response.  The maximum of the TBARS 
chromophore is cited to lie at 532 nm; however my experimental data shows it at 540 
nm.  Data taken at each wavelength were comparable, and measurements were continued 
at 532 nm to comply with convention.  The TBARS assay is a satisfactory method for 
fast determination of extent of oxidation in clinical samples, however its lack of 
specificity requires another detection method to be used simultaneously. 
 Density gradient ultracentrifugation was used to determine the change in mean 
buoyant density of the lipoproteins following oxidation.  The shift in LDL density (as 
measured by tube coordinate) over time is very similar to the TBARS response at 532 
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nm, indicating the density shift is indeed due to oxidation.  HDL also shows mean 
density shifts, although they are not as significant as those seen in LDL.  Determination 
of shift in mean buoyant density of lipoprotein classes is also clinically feasible, and an 
excellent addition to the TBARS assay. 
 Two fluorescent probes were examined for their use in density profiling.  The 
first, NBD, was very successful in both CsBiY and NaBiY density gradients for profiling 
both unoxidized and oxidized samples.  The second, NR, did not show the same density 
shift between unoxidized and oxidized lipoprotein samples.  NR has lower fluorescence 
intensity than NBD in CsBiY, and an even lower intensity in NaBiY.  The decrease in 
intensity causes much detail to be eliminated from the density profile.   
 Two types of sample, human serum and human plasma, were studied.  Density 
profiles showed few differences between the two.  Two types of unoxidized controls 
were examined; one that was kept frozen at -85°C until analysis, and one that was 
incubated at 37°C.  TBARS analysis showed little difference for the two, indicating no 
oxidation took place in either sample due to incubation alone.  For oxidation times of 24 
hours, however, there were distinct differences in the density profiles.  When the 
oxidation time was decreased to 15 hours, the density profiles showed no mean density 
shifts in the lipoproteins. 
 The fluorescent probes utilized in the density profiling were also studied for their 
ability to distinguish small changes in their microenvironment.  NBD showed no change 
between oxidized and unoxidized samples.  The NR, however, showed an increase in 
both emission and excitation maxima for oxidized samples.  Further analysis of the 
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fluorescence maxima shift gave inconsistent results, and the decision was made to forego 
further study of this phenomena. 
 MALDI-TOF-MS was used to study oxidative differences in the apoproteins 
from the HDL fraction.  Apo C-I and apo C-I’ each split into a doublet, with a m/z 
difference of 16 Da indicating conversion of a methionine residue to a sulfoxide.  The 
isoform distribution of SAA4 reversed, indicating oxidation may contribute to truncation.  
SAA4’’ showed an increased m/z of 16 Da, which could also be due to methionine 
conversion.  Apo A-I also formed a doublet, differing in approximately 800 Da, though 
more work must be done to distinguish the mechanism of this change.  Several other 
apoproteins exhibited altered m/z ratios of unknown origin.  Apo C-II and apo A-
IImonomer increased by 10 Da, and apo C-III0, Gly increased by 11 Da.  A new peak was 
observed at 13870 m/z, the origin of which is also unknown. 
 While much work still needs to be done on these methods, they demonstrate 
without doubt that they are capable of distinguishing between unoxidized and oxidized 
samples.  To further support this claim, a pilot clinical study was conducted to examine 
the antioxidant effect of California table grapes.  Density profiles showed significant 
shifts in LDL and HDL mean buoyant density.  MALDI-TOF-MS illustrated differences 
as well, however no peak ratio demonstrated a proportionality to the hypothesized 
oxidation level.   
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